Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) EBT Margin (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed EBT Margin for 3 consecutive years, with 4152.49% as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, EBT Margin fell 359003.0% year-over-year to 4152.49%, compared with a TTM value of 1140.91% through Dec 2024, up 106532.0%, and an annual FY2024 reading of 1598.36%, up 121866.0% over the prior year.
  • EBT Margin was 4152.49% for Q2 2024 at Oramed Pharmaceuticals, down from 259.12% in the prior quarter.
  • Across five years, EBT Margin topped out at 259.12% in Q1 2024 and bottomed at 4152.49% in Q2 2024.
  • Average EBT Margin over 3 years is 1443.97%, with a median of 1206.16% recorded in 2022.
  • The sharpest move saw EBT Margin soared 113145bps in 2023, then tumbled -359003bps in 2024.
  • Year by year, EBT Margin stood at 1363.5% in 2022, then surged by 59bps to 562.46% in 2023, then crashed by -638bps to 4152.49% in 2024.
  • Business Quant data shows EBT Margin for ORMP at 4152.49% in Q2 2024, 259.12% in Q1 2024, and 562.46% in Q2 2023.